Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ: IMVT )

19.52 +0.00 (+0.03%)
Streaming Delayed Price Updated: 10:56 AM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunovant, Inc. - Common Stock

Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
Via Investor Brand Network
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
Via Investor Brand Network
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
From Immunovant Inc.
Via GlobeNewswire
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
From Immunovant Inc.
Via GlobeNewswire
NASDAQ:IMVT Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Immunovant, Inc.
San Diego, CA -- (SBWIRE) -- 05/19/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Immunovant, Inc. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all... 
Via FinancialNewsMedia
Topics Death
Exposures Death
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)
From The Law Offices of Frank R. Cruz
Via Business Wire
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc.
San Diego, CA -- (SBWIRE) -- 04/07/2021 -- A deadline is coming up on April 20, 2021 in the lawsuit filed for certain investors of Immunovant, Inc. (NASDAQ:IMVT). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.